Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Chest computed tomography : a validated surrogate endpoint of cystic fibrosis lung disease? / Loeve, Martine; Krestin, Gabriel P.; Rosenfeld, Margaret; de Bruijne, Marleen; Stick, Stephen M.; Tiddens, Harm A.

I: European Respiratory Journal, Bind 42, Nr. 3, 2013, s. 844-857.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Loeve, M, Krestin, GP, Rosenfeld, M, de Bruijne, M, Stick, SM & Tiddens, HA 2013, 'Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease?', European Respiratory Journal, bind 42, nr. 3, s. 844-857. https://doi.org/10.1183/09031936.00051512

APA

Loeve, M., Krestin, G. P., Rosenfeld, M., de Bruijne, M., Stick, S. M., & Tiddens, H. A. (2013). Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease? European Respiratory Journal, 42(3), 844-857. https://doi.org/10.1183/09031936.00051512

Vancouver

Loeve M, Krestin GP, Rosenfeld M, de Bruijne M, Stick SM, Tiddens HA. Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease? European Respiratory Journal. 2013;42(3):844-857. https://doi.org/10.1183/09031936.00051512

Author

Loeve, Martine ; Krestin, Gabriel P. ; Rosenfeld, Margaret ; de Bruijne, Marleen ; Stick, Stephen M. ; Tiddens, Harm A. / Chest computed tomography : a validated surrogate endpoint of cystic fibrosis lung disease?. I: European Respiratory Journal. 2013 ; Bind 42, Nr. 3. s. 844-857.

Bibtex

@article{1dab54777058428c95c409414140f837,
title = "Chest computed tomography: a validated surrogate endpoint of cystic fibrosis lung disease?",
abstract = "Clinical trials for the treatment of cystic fibrosis (CF) lung disease are important to test and optimize new therapeutic interventions. To evaluate the effect of these interventions, sensitive and accurate outcome measures are needed. The most commonly used endpoints are spirometric variables such as the forced expiratory volume in one second (FEV1) and respiratory tract exacerbations (RTE). Unfortunately, these endpoints are relatively insensitive to monitor progression of CF lung disease, and thus require a large number of patients when used in clinical studies. In addition, these endpoints are not suitable to study CF lung disease in young children. Chest computed tomography (CT) holds great promise for use as a sensitive surrogate endpoint in CF. A large body of evidence has been produced to validate the use of chest CT as primary endpoint to study CF lung disease. However, before chest CT can be used in clinical trials, it has to be recognized as a validated surrogate endpoint by regulatory agencies. The aim of this review is to summarize what is currently known about the use of chest CT as surrogate endpoint in clinical trials in CF.",
author = "Martine Loeve and Krestin, {Gabriel P.} and Margaret Rosenfeld and {de Bruijne}, Marleen and Stick, {Stephen M.} and Tiddens, {Harm A.}",
year = "2013",
doi = "10.1183/09031936.00051512",
language = "English",
volume = "42",
pages = "844--857",
journal = "The European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",

}

RIS

TY - JOUR

T1 - Chest computed tomography

T2 - a validated surrogate endpoint of cystic fibrosis lung disease?

AU - Loeve, Martine

AU - Krestin, Gabriel P.

AU - Rosenfeld, Margaret

AU - de Bruijne, Marleen

AU - Stick, Stephen M.

AU - Tiddens, Harm A.

PY - 2013

Y1 - 2013

N2 - Clinical trials for the treatment of cystic fibrosis (CF) lung disease are important to test and optimize new therapeutic interventions. To evaluate the effect of these interventions, sensitive and accurate outcome measures are needed. The most commonly used endpoints are spirometric variables such as the forced expiratory volume in one second (FEV1) and respiratory tract exacerbations (RTE). Unfortunately, these endpoints are relatively insensitive to monitor progression of CF lung disease, and thus require a large number of patients when used in clinical studies. In addition, these endpoints are not suitable to study CF lung disease in young children. Chest computed tomography (CT) holds great promise for use as a sensitive surrogate endpoint in CF. A large body of evidence has been produced to validate the use of chest CT as primary endpoint to study CF lung disease. However, before chest CT can be used in clinical trials, it has to be recognized as a validated surrogate endpoint by regulatory agencies. The aim of this review is to summarize what is currently known about the use of chest CT as surrogate endpoint in clinical trials in CF.

AB - Clinical trials for the treatment of cystic fibrosis (CF) lung disease are important to test and optimize new therapeutic interventions. To evaluate the effect of these interventions, sensitive and accurate outcome measures are needed. The most commonly used endpoints are spirometric variables such as the forced expiratory volume in one second (FEV1) and respiratory tract exacerbations (RTE). Unfortunately, these endpoints are relatively insensitive to monitor progression of CF lung disease, and thus require a large number of patients when used in clinical studies. In addition, these endpoints are not suitable to study CF lung disease in young children. Chest computed tomography (CT) holds great promise for use as a sensitive surrogate endpoint in CF. A large body of evidence has been produced to validate the use of chest CT as primary endpoint to study CF lung disease. However, before chest CT can be used in clinical trials, it has to be recognized as a validated surrogate endpoint by regulatory agencies. The aim of this review is to summarize what is currently known about the use of chest CT as surrogate endpoint in clinical trials in CF.

U2 - 10.1183/09031936.00051512

DO - 10.1183/09031936.00051512

M3 - Journal article

VL - 42

SP - 844

EP - 857

JO - The European Respiratory Journal

JF - The European Respiratory Journal

SN - 0903-1936

IS - 3

ER -

ID: 44489856